Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 7/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | GAPDH | P04406 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CACNA1H | O95180 | 6/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1257156 | 0.96 | KIT (0.53) | KITFLT3GAPDHMEN1KMT2A | |
| SCHEMBL1257174 | 0.85 | KIT (0.60) | KITFLT3 | |
| SCHEMBL1255093 | 0.83 | GAPDH (0.52) | KITGAPDHMEN1KMT2ANPC1 | |
| SCHEMBL1256318 | 0.83 | GAPDH (0.46) | KITGAPDHMEN1KMT2ANPC1 | |
| SCHEMBL1257147 | 0.82 | KIT (0.53) | KITFLT3GAPDHKDM4ECACNA1H | |
| SCHEMBL1256991 | 0.81 | KIT (0.63) | KITFLT3CACNA1H | |
| SCHEMBL1256304 | 0.81 | GAPDH (0.47) | KITGAPDHMEN1KMT2ANPC1 | |
| SCHEMBL1255130 | 0.81 | GAPDH (0.50) | KITGAPDHMEN1KMT2ANPC1 | |
| SCHEMBL1256119 | 0.81 | KIT (0.63) | KITFLT3CACNA1H | |
| SCHEMBL16536880 | 0.81 | KIT (0.56) | KITFLT3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2013-02-07 | — | — | US | disclosed |
| EP-2467137-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | Ambit Biosciences Corporation (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011022473-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | AMBIT BIOSCIENCES CORPORATION (US) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130035326-A1 | BIARYL COMPOUNDS AND METHODS OF USE THEREOF | FLT3, CSF3R, CSF1R | KIT 4/4885FLT3 1/4885GAPDH 1316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.